Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome

Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends the lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome, a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae...

Full description

Bibliographic Details

Published in:	eLife
Main Authors:	Sae-Il Murtada, Nicole Mikush, Mo Wang, Pengwei Ren, Yuki Kawamura, Abhay B Ramachandra, David S Li, Demetrios T Braddock, George Tellides, Leslie B Gordon, Jay D Humphrey
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2023-03-01
Subjects:	lamin A progeria lonafarnib aorta cardiac function survival
Online Access:	https://elifesciences.org/articles/82728